Unknown PHASE2 INTERVENTIONAL 2-arm NCT01393184

Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN

Prospective, Randomized, Controlled, Phase II，Multiple Centered Clinical Trial of Nimotuzumab Combined With Radiotherapy for Senile Locally Advanced SCCHN

Sponsor: Biotech Pharmaceutical Co., Ltd.

Conditions SCCHN

Interventions Nimotuzumab and Radiotherapy

Updated 6 times since 2017 Last updated: Jul 12, 2011 Started: Mar 31, 2011 Primary completion: Feb 28, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01393184, this PHASE2 trial focuses on SCCHN and remains ongoing. Sponsored by Biotech Pharmaceutical Co., Ltd., it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Enrolling By Invitation → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE2

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biotech Pharmaceutical Co., Ltd.
Peking University

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.